Paper34066940
Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.
Fajardo-Orduña GR and 5 others. Int J Mol Sci, 2021. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review. Papers, record 34066940. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34066940
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytarabine | Major topic |
| Drug Resistance, Multiple | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Animals | |
| Cell Death | |
| Humans | |
| Models, Biological |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PAPIIT IN229820 | General Directorate of Academic Personnel Affairs, National Autonomous University of Mexico | PubMed |
Source PubMed
References98
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30228301 | Stem cell fate in cancer growth, progression and therapy resistance. | Nat Rev Cancer | 2018 | https://conductscience.org/library/papers/30228301 | PubMed |
| 2 | 28123146 | Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives. | Biosci Trends | 2017 | https://conductscience.org/library/papers/28123146 | PubMed |
| 3 | 26265695 | Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. | Blood | 2015 | https://conductscience.org/library/papers/26265695 | PubMed |
| 4 | 29164055 | microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview. | Front Oncol | 2017 | https://conductscience.org/library/papers/29164055 | PubMed |
| 5 | 27973410 | Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/27973410 | PubMed |
| 6 | 28286924 | Treatment of Relapsed/Refractory Acute Myeloid Leukemia. | Curr Treat Options Oncol | 2017 | https://conductscience.org/library/papers/28286924 | PubMed |
| 7 | 32601974 | Treatment of Relapsed Acute Myeloid Leukemia. | Curr Treat Options Oncol | 2020 | https://conductscience.org/library/papers/32601974 | PubMed |
| 8 | 25744718 | CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. | Cancer Res | 2015 | https://conductscience.org/library/papers/25744718 | PubMed |
| 9 | 22869556 | Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22869556 | PubMed |
| 10 | 17054996 | Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. | J Surg Res | 2006 | https://conductscience.org/library/papers/17054996 | PubMed |
| 11 | 25322685 | Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. | Leukemia | 2015 | https://conductscience.org/library/papers/25322685 | PubMed |
| 12 | 32657052 | Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. | Stem Cells Transl Med | 2020 | https://conductscience.org/library/papers/32657052 | PubMed |
| 13 | 22850751 | Overcoming implementation challenges of personalized cancer therapy. | Nat Rev Clin Oncol | 2012 | https://conductscience.org/library/papers/22850751 | PubMed |
| 14 | 19842938 | Genetic factors influencing cytarabine therapy. | Pharmacogenomics | 2009 | https://conductscience.org/library/papers/19842938 | PubMed |
| 15 | 17975014 | CREB is a critical regulator of normal hematopoiesis and leukemogenesis. | Blood | 2008 | https://conductscience.org/library/papers/17975014 | PubMed |
| 16 | 23676220 | Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. | Cell Cycle | 2013 | https://conductscience.org/library/papers/23676220 | PubMed |
| 17 | 24756163 | miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. | Int J Oncol | 2014 | https://conductscience.org/library/papers/24756163 | PubMed |
| 18 | 30420752 | Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. | Nat Med | 2018 | https://conductscience.org/library/papers/30420752 | PubMed |
| 19 | 22383795 | Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. | Blood | 2012 | https://conductscience.org/library/papers/22383795 | PubMed |
| 20 | 23087055 | Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). | Cancer Res | 2012 | https://conductscience.org/library/papers/23087055 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42469871 | TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia. | J Transl Med | 2026 | https://conductscience.org/library/papers/42469871 | PubMed |
| 42310288 | Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42310288 | PubMed |
| 42266667 | miR-2110 orchestrates ERK-ELK1 transcriptional repression to induce cell-cycle arrest and enhance cytarabine sensitivity in acute myeloid leukemia. | Front Oncol | 2026 | https://conductscience.org/library/papers/42266667 | PubMed |
| 42143046 | Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML. | Oncogenesis | 2026 | https://conductscience.org/library/papers/42143046 | PubMed |
| 41912486 | Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41912486 | PubMed |
| 41748545 | RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41748545 | PubMed |
| 41471781 | Antileukemic Potential of Sodium Caseinate in Cytarabine-Resistant HL60-CR50 Human Leukemia Cells. | Molecules | 2025 | https://conductscience.org/library/papers/41471781 | PubMed |
| 41317290 | Therapeutic potential of metformin-based combination therapy in acute myeloid leukemia. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41317290 | PubMed |
| 40806596 | Sodium Caseinate Induces Apoptosis in Cytarabine-Resistant AML by Modulating SIRT1 and Chemoresistance Genes, Alone or in Combination with Cytarabine or Daunorubicin. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806596 | PubMed |
| 40427634 | The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid Leukemia. | Biomolecules | 2025 | https://conductscience.org/library/papers/40427634 | PubMed |
| 40275490 | ARF6 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling. | Cancer Med | 2025 | https://conductscience.org/library/papers/40275490 | PubMed |
| 39767527 | Protective Effect of Silver Nanoparticles Against Cytosine Arabinoside Genotoxicity: An In Vivo Micronucleus Assay. | Int J Environ Res Public Health | 2024 | https://conductscience.org/library/papers/39767527 | PubMed |
| 39469152 | CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia. | Indian J Hematol Blood Transfus | 2024 | https://conductscience.org/library/papers/39469152 | PubMed |
| 39339789 | Antineoplastic Activity of Sodium Caseinate in a Cytarabine-Resistant Mouse Acute Myeloid Leukemia Cell Line. | Nutrients | 2024 | https://conductscience.org/library/papers/39339789 | PubMed |
| 39036603 | Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges. | Noncoding RNA Res | 2024 | https://conductscience.org/library/papers/39036603 | PubMed |
| 38910243 | Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis. | Biol Direct | 2024 | https://conductscience.org/library/papers/38910243 | PubMed |
| 38892165 | The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892165 | PubMed |
| 38699598 | Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation. | Saudi Pharm J | 2024 | https://conductscience.org/library/papers/38699598 | PubMed |
| 37665348 | E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia. | Ann Hematol | 2023 | https://conductscience.org/library/papers/37665348 | PubMed |
| 37623484 | Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients. | J Pers Med | 2023 | https://conductscience.org/library/papers/37623484 | PubMed |
Genes80
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34066940
GET https://conductscience.org/api/papers/v1/34066940/references?page=2